## **BMPR2-IN-1 TFA**

Cat. No.:	HY-154970A		
Molecular Formula:	$C_{18}H_{16}F_{3}N_{7}O_{3}$		
Molecular Weight:	435.36		0
Target:	TGF-β Receptor	H H	F, Lau
Pathway:	TGF-beta/Smad		F OH
Storage:	<b>4°C, protect from light, stored under nitrogen</b> * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)		

### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (229.69 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.2969 mL	11.4847 mL	22.9695 mL	
		5 mM	0.4594 mL	2.2969 mL	4.5939 mL	
		10 mM	0.2297 mL	1.1485 mL	2.2969 mL	
	Please refer to the sol	ubility information to select the ap	propriate solvent.			
In Vivo	1. Add each solvent o Solubility: ≥ 2.5 mg	one by one: 10% DMSO >> 40% PE g/mL (5.74 mM); Clear solution	G300 >> 5% Tween-80	) >> 45% saline		
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution					
	3. Add each solvent o Solubility: ≥ 2.5 mg	one by one: 10% DMSO >> 90% co g/mL (5.74 mM); Clear solution	rn oil			

OLOGICAL ACTIV	ТТҮ
Description	BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC <sub>50</sub> of 506 nM and a K <sub>D</sub> of 83.5 nM. BMPR2-IN-1 can be used research of pulmonary arterial hypertension, Alzheimer's disease and cancer <sup>[1]</sup> .

#### REFERENCES

[1]. Amrhein JA, et al. Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2. ACS Med Chem Lett. 2023 May 30;14(6):833-840.

# **Product** Data Sheet



#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA